肺表面活性物质治疗新生儿肺透明膜病的疗效观察

Clinical observation of hyaline membrane disease with pulmonary surfactant

目的探讨肺表面活性物质早期给药对新生儿肺透明膜病疗效的观察。方法对19例患新生儿肺透明膜病的极低出生体重儿给予肺表面活性物质治疗并同时进行临床对照试验。结果新生儿肺透明膜病患儿给药后24hPO2／FiO2较用药前明显改善，差异显著（P〈0．05），呼吸机参数（除PEEP外）明显下降，差异有统计学意义（P〈0．05）。结论对于极低出生体重的新生儿肺透明膜病患儿，早期给予肺表面活性物质治疗可明显改善近期预后，提高存活率。

Objective To observing the effect of pulmonary surfactant （PS） in the hyaline membrane disease （HMD）. Methods 19 patients suffering from HMD a very low - birth - weight children given PS treatment and at the same time of clinical controlled trials. Results After given PS 24 hours, the PO2/FiO2 and parameter of respirator utilization ascended significantly, there were significant difference （ P 〈 0.05 ）. Conclusion The strategy of surfaetant treatment in early phase can significantly improve the survival of very low birth weight infants with HMD.